GLPwatch
Adlyxin vs Ozempic
Drug comparison
Last updated 2026-05-28 15:46 UTCAdlyxin (lixisenatide) and Ozempic (semaglutide) are both injectable medications for type 2 diabetes, made by different companies (Sanofi and Novo Nordisk, respectively). Ozempic is also FDA-approved to reduce cardiovascular risk and treat chronic kidney disease, while Adlyxin is only approved for diabetes. Both are taken as weekly shots under the skin, but they contain different active ingredients.
AI summary of the sources below.
| Adlyxin | Ozempic | |
|---|---|---|
| Active ingredient | lixisenatide | semaglutide |
| Manufacturer | sanofi | novo-nordisk |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes | type 2 diabetes, cardiovascular risk reduction, chronic kidney disease |
| Label updated | — | 2026-01-30 |